Estrogen (Estradiol) — Role in Fertility, Follicle Development & IVF Monitoring

Oestrogen (spelt "estrogen" in American usage) refers to a group of female sex hormones — oestradiol (E2) is the most potent and important form in reproductive-age women. Oestrogen is produced by growing ovarian follicles and has several key fertility functions: (1) Drives endometrial growth — thickens the uterine lining each cycle to prepare for embryo implantation; (2) Triggers the LH surge at mid-cycle — when oestradiol rises sufficiently, it signals the pituitary to release the LH surge → ovulation; (3) Stimulates cervical mucus production — "fertile" egg-white cervical mucus that helps sperm travel to the egg; (4) Supports follicle development and oestradiol is the direct product of healthy follicle growth.

Oestradiol (E2) is the active oestrogen produced by granulosa cells of growing follicles. During IVF stimulation, serum E2 is measured every 2–3 days alongside transvaginal ultrasound to monitor how your follicles are responding. Each mature follicle (≥17mm) produces approximately 200–300 pg/mL of E2. So: 5 mature follicles → expected E2 ~1,000–1,500 pg/mL; 15 mature follicles → expected E2 ~3,000–4,500 pg/mL. Rising E2 confirms follicle growth. If E2 rises too fast with many follicles → OHSS risk → dose reduction or trigger change needed.

A peak serum oestradiol (E2) above 4,000–5,000 pg/mL, combined with more than 15–20 follicles >11mm, signals a high risk of OHSS (ovarian hyperstimulation syndrome) — a potentially serious complication of IVF. When E2 is too high, your fertility team will: (1) Consider "coasting" — withholding FSH injections for 1–2 days to allow smaller follicles to regress and E2 to fall; (2) Switch from hCG trigger to GnRH agonist trigger (e.g., Buserelin 0.5mg SC) — this triggers ovulation with less OHSS risk; (3) Recommend a "freeze-all" cycle — all embryos frozen, no fresh embryo transfer; FET in a subsequent cycle when OHSS risk has resolved.

In medicated FET cycles, natural oestrogen production is not relied upon — instead, exogenous oestrogen is given to grow the endometrium. The standard protocol: Days 1–2: start oestradiol valerate tablets (Progynova) 2mg three times daily, or oestrogen patches; Days 10–12: transvaginal scan to measure endometrial thickness (aim ≥7–8mm) and assess trilaminar pattern; if thickness adequate (≥7mm): add progesterone pessaries — embryo transfer planned 5–6 days later (blastocyst transfer); if endometrium thin (<7mm): increase oestrogen dose, add vaginal sildenafil or low-dose aspirin to improve blood flow.

As women approach menopause, the ovarian follicle pool depletes, and oestrogen (oestradiol) production falls progressively. This decline accelerates in the late 40s, but can begin earlier in women with premature ovarian insufficiency (POI). Consequences for fertility and health: endometrial atrophy (thinning of the uterine lining — embryo implantation impaired); hot flushes and night sweats; vaginal dryness and discomfort; accelerated bone loss (osteoporosis); cardiovascular risk increase. For women with POI (menopause before 40), hormone replacement therapy (HRT) with oestrogen + progestogen is strongly recommended until at least age 51 — for bone protection, cardiovascular health, and quality of life. Fertility after menopause is only possible using donor eggs with exogenous oestrogen endometrial preparation.